Claims for Patent: 9,439,852

Summary for Patent: 9,439,852

Title:	Methods of delivering pharmaceutical agents
Abstract:	Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.
Inventor(s):	Bleier; Benjamin S. (Weston, MA)
Assignee:	Massachusetts Eye & Ear Infirmary (Boston, MA)
Application Number:	14/739,872
Patent Claims:	1. A method of delivering at least one pharmaceutical agent to the central nervous system of a subject diagnosed with a brain cancer, the method comprising directly administering at least one pharmaceutical agent onto a semipermeable epithelial membrane (SEM) graft in the skull base of the subject. 2. The method of claim 1, wherein the at least one pharmaceutical agent is administered into an endonasal reservoir. 3. The method of claim 1, wherein the at least one pharmaceutical agent is placed into an endonasal reservoir device in an endogenous sinus tissue of the subject, wherein the device comprises at least one opening or permeable surface proximal to the SEM graft in the skull base and the at least one pharmaceutical agent in the endonasal reservoir device is administered onto the SEM graft in the skull base. 4. The method of claim 1, further comprising forming a semipermeable epithelial membrane (SEM) graft in the skull base of the subject. 5. The method of claim 4, further comprising forming a SEM graft over an endogenous sinus tissue or in a position proximal to the SEM graft in the skull base, where the SEM graft over the endogenous sinus tissue or in the position proximal to the SEM graft in the skull base forms an endonasal reservoir. 6. The method of claim 4, further comprising: introducing an endonasal reservoir device comprising at least one opening or permeable surface into an endogenous sinus tissue of the subject; and placing the at least one pharmaceutical agent into the endonasal reservoir device; wherein the at least one opening or permeable surface is proximal to the SEM graft in the skull base and the at least one pharmaceutical agent in the endonasal reservoir device is administered onto the SEM graft in the skull base. 7. The method of claim 1, wherein the forming, introducing, placing, or administering is performed by an endoscopic or interfacial procedure. 8. The method of claim 1, wherein the SEM graft in the skull base is formed from sinonasal mucosa. 9. The method of claim 1, wherein the SEM graft in the skull base is formed in the posterior frontal table, cribiform plate/ethmoid roof, planum sphenoidale, tuberculum, sella, clival recess, clivus, or cervical spine. 10. The method of claim 1, wherein the at least one pharmaceutical agent is formulated as a component of a biodegradable biocompatible polymer. 11. The method of claim 10, wherein the biodegradable biocompatible polymer is cationic. 12. The method of claim 10, wherein the biodegradable biocompatible polymer is a gel. 13. The method of claim 12, wherein the gel is an alginate gel, a cellulose-based gel, or a chitosan-based gel. 14. The method of claim 13, wherein the alginate gel is sodium alginate. 15. The method of claim 13, wherein the cellulose-based gel is carboxymethyl cellulose or carboxyethyl cellulose. 16. The method of claim 13, wherein the chitosan-based gel is chitosan glycerophosphate. 17. The method of claim 1, wherein the at least one pharmaceutical agent is formulated as a liquid. 18. The method of claim 17, wherein the liquid is a thermosetting liquid. 19. The method of any claim 1, wherein the at least one pharmaceutical agent is administered in a sustained-release formulation. 20. The method of claim 1, wherein the at least one pharmaceutical agent has a molecular size of greater than 500 Daltons, has a net negative or positive charge, or is a polar molecule. 21. The method of claim 1, wherein the at least one pharmaceutical agent comprises a chemotherapeutic agent. 22. The method claim 21, wherein the chemotherapeutic agent is selected from the group consisting of: cyclophosphamide, mechlorethamine, chlorabucil, melphalan, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, paclitaxel, docetaxel, etoposide, teniposide, tafluposide, azacitidine, axathioprine, capecitabine, cytarabine, doxifluridine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, tioguanine, bleomycin, carboplatin, cisplatin, oxaliplatin, all-trans retinoic acid, vinblastine, vincristine, vindesine, vinorelbine, and bevacizumab. 23. The method of claim 1, wherein the brain cancer is selected from the group consisting of: glioblastoma multiforme, oligodendroglioma, astrocytoma, oligogastrocytoma, ependymoma, medulloblastoma, and meningioma.

Details for Patent 9,439,852

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-07-29